Economic end points in phase II trials

Am Heart J. 2000 Apr;139(4):S155-7. doi: 10.1016/s0002-8703(00)90063-2.
No abstract available

MeSH terms

  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / economics*
  • Cardiovascular Agents / therapeutic use
  • Clinical Trials, Phase II as Topic / economics*
  • Cost-Benefit Analysis
  • Humans
  • Treatment Outcome

Substances

  • Cardiovascular Agents